免疫调节治疗下炎症性肠病患者中保存的 SARS-CoV-2 疫苗细胞介导免疫原性。
Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies.
机构信息
Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
出版信息
Clin Transl Gastroenterol. 2022 Apr 1;13(4):e00484. doi: 10.14309/ctg.0000000000000484.
Immune-modulating medications for inflammatory bowel diseases (IBDs) have been associated with suboptimal vaccine responses. There are conflicting data with SARS-CoV-2 vaccination. We therefore assessed SARS-CoV-2 vaccine immunogenicity at 2 weeks after second mRNA vaccination in 29 patients with IBD compared with 12 normal healthy donors. We observed reduced humoral immunity in patients with IBD on infliximab. However, we observed no difference in humoral and cell-mediated immunity in patients with IBD on infliximab with a thiopurine or vedolizumab compared with normal healthy donors. This is the first study to demonstrate comparable cell-mediated immunity with SARS-CoV-2 vaccination in patients with IBD treated with different immune-modulating medications.
免疫调节药物治疗炎症性肠病（IBD）与疫苗应答不理想有关。关于 SARS-CoV-2 疫苗接种的数据存在矛盾。因此，我们比较了 29 例 IBD 患者和 12 例正常健康供者在第二次 mRNA 疫苗接种后 2 周时的 SARS-CoV-2 疫苗免疫原性。我们观察到英夫利昔单抗治疗的 IBD 患者的体液免疫降低。然而，与正常健康供者相比，英夫利昔单抗联合硫唑嘌呤或维得利珠单抗治疗的 IBD 患者在体液和细胞介导免疫方面没有差异。这是第一项表明不同免疫调节药物治疗的 IBD 患者在 SARS-CoV-2 疫苗接种后具有相似细胞介导免疫的研究。
Zotero 插件